Heterogeneity in adverse event assessment between countries participating in an international collaboration of registries of Rheumatoid Arthritis patients using Janus Kinase inhibitors (the JAK-POT study)
14/08/2023
K. Lauper1 , D. Mongin1 , S. A. Bergstra2 , D. Choquette3 , C. Codreanu4 , D. De Cock5 , L. Dreyer6 , O. Elkayam7 , K. Hyrich8 , F. Iannone9 , N. Inanc10, E. Kristianslund11, T. K. Kvien11, B. Leeb12, G. Lukina13, D. Nordström14, K. Pavelka15, M. Pombo-Suarez16, Z. Rotar17, M. J. Santos18,19, A. Strangfeld20, D. Courvoisier1 , A. Finckh1 on behalf of Epidemiology and registry working group
EULAR 2021
DOI: 10.1136/annrheumdis-2021-eular.2216
https://ard.bmj.com/content/80/Suppl_1/256